# Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia

> **NCT01890694** · PHASE4 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 2 (actual)

## Conditions studied

- Hyponatremia

## Interventions

- **DRUG:** Tolvaptan
- **DRUG:** Placebo
- **BEHAVIORAL:** Hepatic Encephalopathy Assessment
- **BEHAVIORAL:** Quality of Life Assessment
- **BIOLOGICAL:** Vital signs
- **BIOLOGICAL:** Blood laboratory tests
- **PROCEDURE:** Ascites Evaluation
- **PROCEDURE:** Edema

## Key facts

- **NCT ID:** NCT01890694
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2017-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01890694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01890694, "Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01890694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*